Xyflo 10

• Presentation:
  • Each tablet contains 10 mg of Montelukast Sodium.
  • Available in strips of [mention typical strip size, e.g., 3 x 10
• Indications:
  • Prophylaxis and chronic treatment of asthma.  
  • Acute prevention of Exercise-Induced Bronchoconstriction (EIB).  
  • Relief of symptoms of Allergic Rhinitis (AR): Seasonal & Perennial Allergic Rhinitis.  
• Dosage and Administration:
  • Adults and adolescents (15 years of age and older): 10 mg tablet once daily.
  • Pediatric patients with asthma or seasonal allergic rhinitis: Dosage and safety have been established in studies for pediatric patients with asthma 6 months to 14 years of age.
  • No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency, renal insufficiency, or in the elderly.
  • For acute prevention of EIB, administer one 10 mg tablet at least 2 hours before exercise. An additional dose should not be taken within 24 hours of a previous dose.
• Pharmacology:  
  • Montelukast is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene receptor (CysLT1).Cysteinyl leukotrienes (LTC4, LTD4, LTE4) are products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils. They contribute to the pathophysiology of asthma and allergic rhinitis by causing airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process. Montelukast inhibits these effects.   
• Side Effects:
  • Common side effects may include headache.
  • Rare side effects may include angioedema, concentration impaired, disorientation, eosinophilic granulomatosis with polyangiitis, erythema nodosum, hallucination, hepatic disorders, memory loss, palpitations, pulmonary eosinophilia, suicidal tendencies, tremor.  
• Precautions:
  • Xyflo is not indicated for use in the reversal of bronchospasm in acute asthma attacks. Patients should have appropriate rescue medication available.
  • Therapy with Xyflo can be continued during acute exacerbations of asthma.
  • Xyflo should not be abruptly substituted for inhaled or oral corticosteroids, although the dose of inhaled corticosteroids may be reduced gradually under medical supervision.
  • Xyflo should not be used as monotherapy for the treatment and management of exercise-induced bronchospasm.
  • Use with caution in patients with phenylketonuria as the chewable tablets contain phenylalanine.
• Pregnancy & Lactation:
  • Montelukast crosses the placenta in rats and rabbits. There are no adequate and well-controlled studies in pregnant women. Montelukast should be used during pregnancy only if clearly needed.  
  • It is not known if montelukast is excreted in human breast milk. Caution should be exercised when administering montelukast to a nursing woman.
• Storage:
  • Store in a cool and dry place below 30°C, protect from light & moisture.
  • Keep out of reach of children.
• Therapeutic Class:
  • Leukotriene receptor antagonists.

Important Note: This information is for general knowledge and informational purposes only and does not substitute professional medical advice. Always consult your doctor or pharmacist for specific instructions and guidance regarding your medication. They can assess your individual medical condition and provide the most appropriate advice.